BofA analyst Lyanne Harrison raised the firm’s price target on ResMed to $230 from $225 and keeps a Buy rating on the shares. The firm is “more bullish” on Q4 than the Street and sees the outlook as bullish in FY25, seeing a AS11 supply increase and competitor recall tailwinds supporting revenue growth, the analyst tells investors in a preview note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Disney, MicroStrategy initiated: Wall Street’s top analyst calls
- Oppenheimer downgrades ResMed on sleep apnea GLP-1 risk
- ResMed downgraded to Perform from Outperform at Oppenheimer